RedHill Biopharma | RDHL - Ebitda

Stock Price
0.87
Daily Change
-0.01 -1.14%
Monthly
-14.71%
Yearly
-66.02%
Q1 Forecast
0.84

RedHill Biopharma reported $2.69M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
Cronos Group USD 456K 5.22M Dec/2025
RedHill Biopharma USD 2.69M 108.46M Jun/2023